Please login to the form below

Not currently logged in
Email:
Password:

cell therapies

This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

The Marburg site is fully equipped for the production of recombinant proteins as well as cell and gene therapies, with Novartis having significantly invested in the site over the past five

Latest news

  • Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

    At the time the biotech said it would focus on potential therapies for cancer and autoimmune conditions, with its operations supported by GSK’s drug discovery capabilities. ... The biotech says correcting immune cell function or inhibiting tumour cell

  • FDA approves Roche’s Actemra COVID-19 trial FDA approves Roche’s Actemra COVID-19 trial

    It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.

  • China backs use of Roche’s Actemra for coronavirus China backs use of Roche’s Actemra for coronavirus

    It was first cleared by the US Food and Drug Administration (FDA) as a treatment for rheumatoid arthritis and subsequently picked up additional approvals in juvenile idiopathic arthritis, giant cell arteritis ... and CRS associated with CAR-T cell

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    Studies have also suggested that blocking CD47 can send some tumour cells into programmed cell death (apoptosis). ... Magrolimab complements our existing work in haematology, adding a non-cell therapy programme that complements Kite’s pipeline of cell

  • Takeda buys coeliac disease partner PvP Biologics after phase 1 win Takeda buys coeliac disease partner PvP Biologics after phase 1 win

    Takeda paid up to $100 million in funding to deploy GammaDelta’s T cell platform to find new therapies for cancer and autoimmune/inflammatory diseases. ... potentially lucrative market for a disease that affect millions of people around the world and

More from news
Approximately 2 fully matching, plus 134 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Liso-cel can potentially be the best-in-class anti-CD19 based on its differentiated profile compared with other cell therapies: the therapy is manufactured in a defined 1:1 ratio ... This composition could confer efficacy and safety advantages, including

  • A market-adapted agile approach to launch excellence A market-adapted agile approach to launch excellence

    Niche areas have seen a rise in novel approaches, gene and cell therapies, and digital therapies, creating new challenges like stakeholder educational gaps, supply chain barriers.

  • Rethinking trials: the pros and cons of protocol amendments Rethinking trials: the pros and cons of protocol amendments

    Product complexity. The drug industry’s evolution from a provider of chemical-based medicine into a developer of larger molecule drugs and cell and gene therapies is likely to result in ... For example, in the case of a failing lot of autologous cell

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    The number of companies targeting the development of new cell and gene therapies has risen dramatically in recent years. . ... Among ten new cell and gene therapies approved in Europe since 2009, only seven are still commercially available today.

  • Evolution or revolution: the latest review of NICE methods Evolution or revolution: the latest review of NICE methods

    What’s in scope: hot topics including cell and gene therapies and HSTs. ... This is what has happened in previous reviews, such as exploring issues for NICE methods for regenerative and cell therapies or the adoption of changes to tools that measure

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics